BIO recently submitted its Special 301 Submission highlighting intellectual property (IP) challenges around the world. In particular, BIO informed the United States Trade Representative (USTR) of the persistent problems BIO member companies face abroad including global compulsory licensing trends, lack of adequate or any regulatory data protection, restrictive patentability frameworks, and broader market access concerns across the biopharma and agricultural sectors.
During the Special 301 Submission process, USTR collects comments from the public which includes a variety of stakeholders such as the Semiconductor, Video game, Agricultural, Pharmaceutical, Apparel, Manufacturing and other major exporting U.S. industries. Associations that focus on IP issues across industries also weigh in including the International Anti-Counterfeiting Coalition, the U.S. Chamber of Commerce, and the International Intellectual Property Alliance.
USTR will release its final report based on public feedback and its own investigations with embassy officials around the world on or about April 26, 2019.